The National Cancer Institute (NCI) seeks research, co-development, or licensing partners for software that uses computational approaches in cancer diagnosis. NCI researchers have recently developed a computational approach for detecting, quantifying, and mapping Mitotic Hotspots in whole slide images of tumor tissue. This technology has demonstrated high reproducibility that is unaffected by diagnostic skill or fatigue, allowing standardization of tumor cell proliferation assessment across institutions.
The National Cancer Institute seeks licensees for a model used to study molecular mechanisms and/or signaling pathways involved in tumorigenesis, angiogenesis and metastasis of breast cancer and its response to therapy.
Researchers at the National Cancer Institute (NCI) have developed aryl hydantoin heterocycles that target the androgen receptor (AR). NCI seeks research co-development partners and/or licensees to develop these compounds as therapeutics for prostate cancer. As these compounds consist of both AR agonists and antagonists, they may also be effective therapeutics for androgen dysfunctional disorders, such as androgen deficiency disorders or hyperandrogenism.
The National Cancer Institute (NCI) seeks research licensees for a process that reduces nucleic acid (RNA and DNA) degradation and improves protein integrity in tissue preserved as fixed paraffin embedded specimens.
The National Cancer Institute (NCI) seeks research co-development partners or licensees for antisense oligonucleotides that reduce cancer cell migration and invasion. These are expected to be therapeutic against metastatic cancer.
The National Cancer Institute Laboratory of Molecular Biology is seeking statements of capability or interest from parties interested in licensing or collaborative research to further develop, evaluate, or commercialize antibody-based treatments of mesothelin-expressing cancers.
Researchers at the National Cancer Institute (NCI) developed five high-affinity, fully human monoclonal antibodies targeting FLT3. Chimeric antigen receptors (CARs) have also been constructed based on the antibodies identified and tested in animal models of acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL).
Chimeric Antigen Receptor T cell (CAR-T) therapies that specifically target Signaling Lymphocyte Activation Molecule F7 (SLAMF7) are strong therapeutic candidates for patients with Multiple Myeloma (MM). SLAMF7 is highly expressed on the malignant plasma cells that constitute MM. The expression of SLAMF7 by MM cells and lack of expression on nonhematologic cells makes SLAMF7 an attractive therapeutic target for MM. Researchers at the National Cancer Institute (NCI) have invented anti- SLAMF7 CAR constructs that allow genetically-modified T cells to express both the anti-SLAMF7 antibody and a suicide gene that allows T cells to specifically recognize and kill SLAMF7-expressing cells as well as allow for on-demand and reliable elimination of anti-SLAMF7 CAR T cells. NCI seeks licensing and/or co-development partners for this invention.
This technology consists of highly specific rabbit monoclonal antibodies reactive with phosphorylated tyrosine located at amino acid 1235 in the human MET sequence. Binding to this pYl235 residue is independent of the phosphorylation of other tyrosines in the vicinity (1230 and 1234), does not cross-react with these nearby phosphotyrosine residues, and does not occur when Y1235 is unphosphorylated. Researchers at the NCI seek licensing and/or co-development research collaborations to commercialize and develop a companion diagnostic for selective MET inhibitors.
Researchers at NCI developed a rabbit monoclonal antibody that recognizes the marker for CD133 and is useful in pharmacodynamic testing to inform targeted anti-cancer chemotherapy development and clinical monitoring. CD133 is a cell surface glycoprotein used as a marker and expressed in stem cells such as hematopoietic stem cells, endothelial progenitor cells and neural stem cells. The NCI seeks collaborative co-development or licensing partners for this technology.
The National Cancer Institute's Urologic Oncology Branch seeks interested parties to co-develop antagonists to VEGF-A and hepatocyte growth factor (HGF) that block signal transduction and associated cellular responses.
There is a need to develop compounds that can sensitize cancer cells to apoptosis inducing ligands, such as poly I:C and TRAIL. In collaboration with the University of Arizona, NCI investigators discovered a series of compounds in the withanolide family that synergistically enhance the response of cancer cells to treatment with an apoptosis-inducing ligand. The NCI seeks licensing and/or co-development research collaborations for development of withanolide E analogues for the treatment of cancer.
The National Cancer Institute is seeking parties interested in licensing human monoclonal antibodies (mAbs) that bind to death receptor 4 ("DR4"). The tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and its functional receptors, DR4 and DR5, have been recognized as promising targets for cancer treatment.
To date, there is no FDA-approved therapeutic vaccine for human papillomavirus (HPV). Researchers at the National Cancer Institute (NCI) have discovered agonist epitopes for the development of an HPV therapeutic vaccine. NCI is seeking parties interested in licensing and/or co-developing HPV agonist epitopes that enhance the activation of cytotoxic T lymphocytes (CTL) and lysis of human tumor cells.
Researchers at the NCI have developed a method of genetically engineering lymphocytes to expressed elevated levels of cytokine proteins. This technology is useful for improving cellular adoptive immunotherapies to treat a range of infectious diseases and cancers.
Scientists at the National Cancer Institute have developed a cell line designated A549 that was derived from explanted cultures of human lung cancer tissue. The A549 cell line has been tested under the guidance of the United States Food and Drug Administration (FDA) so, under current Good Manufacturing Practices (GMP), these cells may be suitable for use in manufacturing constructs for use in clinical trials. The National Cancer Institute seeks parties to non-exclusively license this research material.
Researchers at the National Cancer Institute (NCI) have identified a biomarker signature of viral infection that correlates with hepatocellular carcinoma (HCC) incidence in at-risk individuals. It has been validated in a longitudinal cohort to detect HCC with high sensitivity and specificity up to 7 years prior to clinical diagnosis. This viral exposure signature can be easily implemented into diagnostic assays for screening of HCC and is available for licensing and/or co-development opportunities.
The National Cancer Institute (NCI) seeks research co-development opportunities and/or licensees for a new biomedical device for biopsy tissue collection and storage in a sterile, well-defined environment.